Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
For a condition that affects nearly 15 percent of the world's population, there are remarkably few effective treatments for migraine sufferers. A new antibody treatment designed specifically for migraine prevention has just completed Phase III human clinical trials with remarkably positive results, raising hopes of a possible revolution on the horizon for sufferers of this debilitating condition.
For the last few years there has been major work examining the role of the calcitonin gene-related peptide (CGRP) in activating migraines. Research has clearly shown that CGRP contributes to the pain conditions of a migraine, so scientists have been working on developing treatments that block the key CGRP receptors in the brain.
